This latest pipeline guide provides comprehensive information on the therapeutics under development for Aplastic Anemia (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Aplastic Anemia (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Aplastic Anemia and features dormant and discontinued projects.
The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 3, 1, 3 and 1 respectively.
- Acceleron Pharma Inc
- Amgen Inc
- BioLineRx Ltd
- F. Hoffmann-La Roche Ltd
- Gamida Cell Ltd
- Novartis AG
- Regen BioPharma Inc
Key Topics Covered
- Report Coverage
- Aplastic Anemia - Overview
- Aplastic Anemia - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Products Under Development by Companies
- Aplastic Anemia - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Aplastic Anemia - Companies Involved in Therapeutics Development
- Aplastic Anemia - Drug Profiles
- Aplastic Anemia - Dormant Projects
- Aplastic Anemia - Discontinued Products
- Aplastic Anemia - Product Development Milestones
- Featured News & Press Releases
For more information about this report visit https://www.researchandmarkets.com/research/gkhdlk/aplastic_anemia?w=4